Voices
Norbert Kraut: Exceptional Panel on ‘Case Studies in Drug Discovery and Development’ at AACR D3
Norbert Kraut/X

Norbert Kraut: Exceptional Panel on ‘Case Studies in Drug Discovery and Development’ at AACR D3

Norbert Kraut, Senior Executive Scientist at Boehringer Ingelheim, shared on LinkedIn:

“Exceptional panel on ‘Case Studies in Drug Discovery and Development’ at the American Association for Cancer Research Drug Discovery and Development (AACR D3) meeting.

Fantastic talks and panel discussion on three cancer drugs newly approved in 2025, covering key challenges and end-to-end insights from lead finding, candidate selection to clinical development strategies.

Thanks to all panelists for an exciting and educational session!

Ralph Neumuller at Boehringer Ingelheim, John Heymach at UT MD ANDERSON CANCER CENTER, Francis Burrows at Kura Oncology, Inc., Eunice S. Wang, Roswell Park Comprehensive Cancer Center, Daisuke Okajima, Daiichi Sankyo, Aditya Bardia, David Geffen, School of Medicine at UCLA”

Norbert Kraut

Other articles featuring Norbert Kraut on OncoDaily.

AACR AACR D3 Aditya Bardia American Association for Cancer Research Drug Discovery and Development cancer Daiichi Sankyo Daisuke Okajima David Geffen Eunice S Wang Francis Burrows John Heymach Norbert Kraut OncoDaily Oncology Ralph Neumuller